Table 1.
Summary of basic clinical and FAP IHC information of the cohort of 15 malignant gliomas
| Sample Number | Pathology | Primary vsersu recurrent | IDH1 Status | Perivascular FAP | Parenchymal FAP |
|---|---|---|---|---|---|
| MGG7 | GBM | Primary | Wild type | – | ++ |
| MGG8 | GBM | Primary | Wild type | – | ++ |
| MGG63 | GBM | Recurrent | Wild type | – | + |
| MGG65 | GBM | Primary | Wild type | – | ++ |
| MGG66 | GBM | Primary | Wild type | – | + |
| MGG67 | GBM | Primary | Wild type | – | + |
| MGG81 | GBM | Primary | Mutant | – | + |
| MGG90 | GBM | Primary | Wild type | – | ++ |
| MGG100 | GBM | Primary | Wild type | – | + |
| MGG125 | GBM | Primary | Wild type | + | + |
| MGG153 | GBM | Primary | Wild type | + | + |
| MGG162 | AA | Primary | Mutant | – | + |
| MGG168 | GBM | Recurrent | Wild type | + | – |
| MGG169 | GBM | Primary | Wild type | – | + |
| MGG225 | GBM | Primary | Wild type | + | + |
GBM, glioblastoma; AA, anaplastic astrocytoma; −, negative, +, 2% or less; ++, 2–10%